Integra Lifesciences Q3 revenue slightly misses estimates on flood damage

Integra LifeSciences Holdings

Yesterday 11:10

Overview
U.S. medical technology firm's Q3 revenue grew 2.3% but slightly missed analyst expectations
Adjusted EPS for Q3 beat analyst expectations
Quarter impacted by Cincinnati flood and weaker Tissue Reconstruction performance

Outlook
Company expects Q4 revenue of $413 mln to $433 mln
Company expects Q4 adjusted EPS of $0.61 to $0.71
Company sees 2026 revenue at $1.634 bln to $1.654 bln

Result Drivers
CINCINNATI FLOOD - Co said Q3 results were negatively impacted by $7 mln in lost revenue due to flood damage at Cincinnati facility
SPECIALTY SURGERY GROWTH - Co said Specialty Surgery segment delivered stronger performance, led by growth in Neurosurgery products
TISSUE RECONSTRUCTION WEAKNESS - Co said Tissue Reconstruction segment declined, with growth in some products offset by declines in others

Company press release: ID:nGNX8zMdqf

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Slight Miss*
$411.20 mln
$414.12 mln (11 Analysts)
Q3 Adjusted EPS
Beat
$0.59
$0.56 (11 Analysts)
Q3 EPS
 
$0.19
 
Q3 Adjusted Net Income
 
$46.40 mln
 
Q3 Adjusted EBITDA
 
$79.80 mln
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 7 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Integra LifeSciences Holdings Corporation is $15.00, about 12.5% above its October 20 closing price of $13.33
The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 7 three months ago

Reuters Recommended Reads
Oct 21 - Sweden's Getinge Q3 organic sales rise 2.1%
Oct 20 - Intuitive Surgical Q3 results top estimates on higher da Vinci system placements
Oct 20 - Iceland's Embla Medical Q3 sales rise on prosthetics demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)